Pulmonx vs Sight Sciences
Pulmonx is the larger business, with $90.5m of revenue in fiscal 2025 against $77.4m for Sight Sciences (1.2 times as much). Pulmonx grew faster (8.0% against -3.1%). Sight Sciences kept more of each dollar of sales as profit: a net margin of -49.7% against -59.7%. Sight Sciences carries less debt relative to equity (66.3% against 78.5%).
| Latest fiscal year | PulmonxLUNG, 2025 | Sight SciencesSGHT, 2025 |
|---|---|---|
| Revenue | $90.5m | $77.4m |
| Revenue growth | 8.0% | -3.1% |
| Net income | −$54.0m | −$38.4m |
| Operating margin | -59.3% | -48.0% |
| Net margin | -59.7% | -49.7% |
| Return on equity | -77.2% | -50.7% |
| Free cash flow | −$32.8m | −$29.9m |
| Cash | $69.8m | $92.0m |
| Total debt | $42.5m | $42.4m |
| Debt to equity | 78.5% | 66.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 296 | 186 |
| Market value | $114m | $516m |
| Price vs our value range | — | — |
| Moat score | 35 (Weak) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 55 sales | 2 buys, 38 sales |